Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) was initiated by National Cancer Institute in 2021 in order to establish an agile and effective network infrastructure to undertake collaborative research focusing on precision cancer prevention and interception, with the overarching goal of discovering molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.
NOT-CA-23-064: Administrative Supplement to Support the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Research
NOT-CA-24-047: Administrative Supplement to Support the NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Research
RFA-CA-21-038, reissued as RFA-CA-22-055: Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)
RFA-CA-21-039, reissued as NOT-CA-23-012: Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Data and Resource Coordination Center (CAP-IT DRCC) (U24 Clinical Trial Not Allowed)
